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THE THERAPEUTIC SUCCESS of anti-
folates has prompted research into the
metabolism of folates in malignant tum-
ours. However, most studies have used
folic acid as a tracer, though this com-
pound is not naturally occurring, and is
only assimilated by an unusual reaction of
DHFR (Gready, 1979). We report the
metabolism of 5-methyltetrahydrofolate
(5MeTHF) a naturally occurring reduced
folate, in rats bearing the Walker 256
carcinosarcoma. This tumour is of special
interest as, in cell culture, it has been
claimed to display methionine auxo-
trophy, while normal cells are able to
survive substitution of methionine by
homocysteine (Halpern et al., 1974). It
has been suggested that other cell lines
with similar properties are deficient in
5MeTHF, requiring methionine synthetase
(Ashe et al., 1974).
This effect, however, is not found in all
tumour cQll lines (Magnum et al., 1969;
Tisdale, 1979) showing that methionine
auxotrophy is a poor indicator of malig-
nancy (Kreis & Goodenow, 1978). With
Walker 256, Hoffman & Erbe (1976)
showed that although the line has a
methionine requirement, both FA and
5MeTHF are equally effective in stimulat-
ing the folate-depleted cell to divide.
The cells are also able to take up 5MeTHF
normally and use it for methionine syn-
thesis at a rate similar to or above normal
cells (Hoffman & Erbe, 1976). Thus, the
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methionine auxotrophy of Walker 256
cells does not arise simply from methionine
synthetase deficiency. However, it might
result from some other difference in
folate metabolism between the tumour
and normal cells.
In these experiments rats bearing the
Walker 256 tumour were dosed with
5[14C]MeTHF to observe one-carbon-
group metabolism, and mixed label [2-14C]
plus [3',5',7,9-3H] 5-MeTHF to observe
the fate of the tetrahydrofolate moiety.
5-MeTHF (Mg salt) was obtained from
Eprova Research Laboratories (Basle,
Switzerland); 5[14C]MeTHF (Ba salt, 88
,Ci/,umol), [2-14C] folic acid (55 buCi/
,umol) and [3',5',7,9-3H] folic acid (500
utCi/,umol) from the Radiochemical Centre
(Amersham, Bucks). Mixed label [2-14C]
plus [3',5',7,9-3H] 5MeTHF, the natural
diastereoisomer, was prepared by orally
dosing rats with a mixture of similarly
labelled folic acid and extracting the
5MeTHF excreted (see below) in the
presence of 0.2% (w/v) sodium ascorbate.
All other substances usedwere of"Analar"
grade or equivalent.
Male Wistar rats (150-200 g) were
obtained from the Chester Beatty
Institute, London. The tumour-bearing
rats had 106 cells of Walker 256 carcino-
sarcoma implanted s.c. on the right
flank. The animals were used in experi-
ments 7 days after implantation, when
tumour mass represented up to 5% body
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TABLE I.-Excreted and retained 14Cfollowing an oral dose of 5[14C]MeTHF (80 ,ug/kg)
in normal rats and those bearing the Walker 256 carcinosarcoma
Day 1 Urine (mean+ s.e.)
2
3
Day 1 CO2
2
3
Day 1 Faeces (mean + s.e.)
2
.3
Day 3 Tissues (mean of 2 values)
Liver
Kidney
Spleen
* Muscle
Tumour
Total
% dose 14C
Normal rats Walker 256-
(4) implanted (6)
50-9 +4-0 46-0+3-3
1-9+ 0-2 4-0+0-33
1-2+ 0-2 2-1+ 0-37
2-0 4-3
0-4 2-1
0-4 2 5
2-3+ 1-0 2-6+0-7
0-1+0-03 0-1+0-05
0-02+ 0-01 0-04+0-01
0-1
0-1
0-01
13 -2
72-7
0-6
0-04
0-6
0-6
68 -3
* Calculated assuming muscle=400% body weight.
weight. Normal males of the same strain
were used as controls.
Radiotracers were dissolved in phos-
phate buffer (pH 7 0, 50 mM) containing
2% (w/v) sodium ascorbate. The animals,
in groups of 4-6, were dosed orally with
up to 2 puCi 14C or 5 pCi 3H of the com-
pound under study. The animals were then
placed in metabolism cages (Jencons,
Herts) which enabled the collection of
expired CO2 (trapped in 100 ml of 2M
NaOH) urine and faeces. Collecting flasks
for urine were protected from light and
contained 5 ml sodium phosphate buffer
(pH 7-0, 50 mM) plus 100 mg sodium
ascorbate. Typically, urine was collected
from 0-6, 6-24, 24-48 and 48-72 h after
administration, with faeces and CO2
collected daily. Throughout this period
the animals had access to food and water
ad libitum. Three days from the start of
the experiment the animals were killed
and the tumour and various organs
excised.
Urine samples and column effluents
were counted as described in Connor
et al., (1979). Faeces and tissues were
freeze-dried, and 100mg samples used to
determine total radioactivity as described
in Barford et al. (1978).
Sephadex G15 gel filtration, DEAE-
cellulose chromatography (Barford, et al.,
1977) and paper chromatography (Connor
et al., 1979) were performed as described
previously.
The distribution and excretion of 14C
activity following an oral dose of 5[14C]-
MeTHF (80 jug/kg) are given in Table I.
The tumour-bearing animals showed
greater production of 14CO2, greater 14C
retention in the liver and less retention in
muscle than normal animals. Chromato-
graphic analysis of the urine samples
showed the presence of 5MeTHF and the
non-folate fraction (NFF; methionine+
creatine) as described in Kennelly et al.
TABLE II.-Ml1etabolites excreted in the
urine of normal and W256 tumour-
bearing rats dosed with 5[14C]MeTHF (80
Kug/kg)
Day 1
NFF
5MeTHF
(% dose)
Normal W 256
3-2 5-2
47-8 34-3
Day 2
NFF 0-52
5MeTHF 1*1
NFF non-folate fraction.
2-3
1*5
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TABLE III.-Excreted (0-3) days and retained radioactivity from rats orally dosed with
[2-14C] + [3',5',7,9-3H] 5MeTHF (normals 8 ,ug/kg; W256-implanted 6 ,ug/kg)
% dose
Normals (5) W 256 (6)
r A , )
14C 3H 14C 3H
Urine (mean + s.e.) 74-2+8-4 92-4+12-8 28-5+2-9 31-5+3-2
Faeces (mean±s.e.) 27-1+2-0 22-0+1-8 5-3+0 5 4-4+0-6
Tissues (mean of 2)
Kidney
Liver
Tumour
0-8
6-8
0 3
ND
1-1
7-2
5-1
1*3
5-7
5*1
(1979). No qualitative difference was
observed between the 2 groups of
animals, but the tumour-bearing animals
showed an absolutely and proportionally
greater excretion of NFF than normals
and less 5-MeTHF excretion (Table II).
Normal and tumour-bearing animals
were dosed orally with [2-14C] + [3',5',7,9-
3H] 5MeTHF at 8 and 6 ,ug/kg respec-
tively. The distribution of radioactivity
recovered is given in Table III. Notably,
excretion of radioactivity in urine and
faeces was less in tumour-bearing rats
than normals (P< 0.001 for both 14C and
3H). The excreted urinary metabolites
were qualitatively similar in the 2 groups;
scission products, 10CHOFA, 5-MeTHF
and an unidentified dual-labelled com-
pound ("folate X" as reported in Saleh
et al., 1981) (Table IV). However, some
TABLE IV.-DEAE-cellUlose fractionation
of first-day urines from animals dosed
orally with [2-14C] + [3',5',7,9-3H]-
5MeTHF
Scission products
lOCHO folate
5MeTHF
Folate X
% dose
, ~ ~ ~~~AA
Normal W256
14C 3H 14C 3H
16-2 6-5
14-1 14-9 4-2 3-8
24-4 32-9 11-7 11-3
15-9 19-7 0 4 4-1
differences were seen in the proportion
of the radioactivity excreted as the
different folates. The 3H-labelled scission
products were separated by Sephadex
G15 into 2 fractions, identified by paper
chromatography (Connor et al., 1979) as
p-acetamidobenzoylglutamate and p-acet-
amidobenzoate. Less of the dose was
catabolized to scission products by the
tumour-bearing animals, despite the reten-
tion of more radioactivity in the tissues.
The presence of an implanted Walker
256 carcinosarcoma imposes changes on
the whole body metabolism of 5MeTHF
in the rat, both of the methyl group and
the tetrahydrofolate moiety. There is more
rapid demethylation and a diversion of
methyl groups from muscle. This is
accompanied by retention ofradioactivity
in the tumour, increased retention in the
liver and increased production of C02
(Table I). As this particular tumour
displays an in vitro methionine require-
ment, the diversion ofmethyl groups from
muscle may be due to the tumour's
demand for methionine, and its meta-
bolism to C02.
Following a dose of mixed label [2-14C]
+ [3',5',7,9-3H]5-MeTHF, markedly less
radioactivity was excreted in the urine
and faeces of the tumour-bearing animals,
indicating that the presence ofthe tumour
increased the demand for folate. Also
folate scission was reduced, both abso-
lutely and as a proportion of the body
burden of folate polyglutamates in the
tumour-bearing animals. Similar observa-
tions have been made using radioactive
folic acid as the tracer (Saleh et al., 1981);
these data confirm the phenomenon with
a naturally occurring reduced folate.
The fact that similar results are obtained
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with folic acid and 5MeTHF also suggests
that the methionine auxotrophy of the
Walker 256 carcinosarcoma is not due
to inability to demethylate 5MeTHF.
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